Loading...
•
Dec 31, 2021
Exact Sciences Q4 2021 Earnings Report
Exact Sciences' financial performance remained steady with revenue growth, driven by Screening and Precision Oncology segments, despite a decrease in COVID-19 testing revenue.
Key Takeaways
Exact Sciences reported Q4 2021 revenue of $473.8 million, a 2% increase compared to Q4 2020. Screening revenue increased by 11%, and Precision Oncology revenue increased by 27%. The company's net loss was $220.6 million, an improvement compared to the net loss of $418.3 million in the same period of the previous year.
Total revenue for Q4 2021 was $473.8 million, a 2% increase year-over-year.
Screening revenue reached $277.7 million, an 11% increase year-over-year.
Precision Oncology revenue was $149.0 million, a 27% increase year-over-year.
COVID-19 testing revenue decreased by 52% to $47.1 million.
Exact Sciences
Exact Sciences
Exact Sciences Revenue by Segment
Revenue by Segment
Screening Revenue
CapyFin.comPrecision Oncology Revenue
CapyFin.com Forward Guidance
The company anticipates revenue of $1.975-$2.027 billion during 2022.
Positive Outlook
- Screening revenue of $1.340-$1.367 billion, including $40-$42 million from PreventionGenetics
- Precision Oncology revenue of $595-$610 million
- COVID-19 testing revenue of $40-$50 million
- Strong momentum from the fourth quarter carrying over to the new year
- Team of talented people dedicated to defeating cancer
Revenue & Expenses
Visualization of income flow from segment revenue to net income